Lineage Cell Therapeutics
LCTX
96 hedge funds and large institutions have $63.2M invested in Lineage Cell Therapeutics in 2019 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 21 increasing their positions, 27 reducing their positions, and 20 closing their positions.
67% more call options, than puts
Call options by funds: $20K | Put options by funds: $12K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.34% less ownership
Funds ownership: 43.42% → 43.08% (-0.34%)
10% less funds holding
Funds holding: 107 → 96 (-11)
11% less capital invested
Capital invested by funds: $71.2M → $63.2M (-$8.04M)
22% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 27
50% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 20
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$205K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$172K |
| 3 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
+$147K |
| 4 |
State Street
Boston,
Massachusetts
|
+$120K |
| 5 |
Nuveen
Charlotte,
North Carolina
|
+$75.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$337K |
| 2 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$135K |
| 3 |
Jane Street
New York
|
-$88.7K |
| 4 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
-$85K |
| 5 |
Barclays
London,
United Kingdom
|
-$79K |
LCTX Hedge Fund Activity: Q3 2019 in Review
96 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q3 2019, worth a combined $63.2M — down 11% from $71.2M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of LCTX and 10 opened new positions — a net loss of 10 holders — while 27 trimmed existing stakes and 21 added.
The largest buyer was BlackRock, adding an estimated $205K. The largest seller was Defender Capital, cutting an estimated $337K.
- 96 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q3 2019, down from 107 in Q2 2019.
- Funds reported $63.2M of Lineage Cell Therapeutics stock for Q3 2019, down 11% quarter-over-quarter.
- 10 funds opened new Lineage Cell Therapeutics positions in Q3 2019 and 20 closed out, a net change of -10 holders.
- The largest Lineage Cell Therapeutics buyer in Q3 2019 was BlackRock, an estimated $205K added.
- The largest Lineage Cell Therapeutics seller in Q3 2019 was Defender Capital, an estimated $337K sold.
Based on aggregated 13F filings for Q3 2019.